Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma

International Journal of Clinical Oncology

Volumn 16, Issue 3, 2011, Pages 221-229

  Kasai, Kazuhiro ^a   Ushio, Akira ^a   Kasai, Yukiho ^a   Sawara, Kei ^a   Miyamoto, Yasuhiro ^a   Oikawa, Kanta ^a   Kuroda, Hidekatsu ^a   Takikawa, Yasuhiro ^a   Suzuki, Kazuyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Hepatocellular carcinoma; PEG ifn 2b; Portal venous invasion

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; FLUOROURACIL; IODINATED POPPYSEED OIL; PEGINTERFERON ALPHA2B;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FAILURE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SURVIVAL RATE; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; INTERFERON ALFA-2B; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052711717     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-010-0151-9     Document Type: Article

References (33)

1. EI-Serag HB, Mason A (1999) Rising incidence of hepatocellular carcinoma in United States. N Engl J Med 340:745-750. (Pubitemid 29114292)
2. Okuda K, Fujimoto I, Hanai A et al (1987) Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 47:4967-4972. (Pubitemid 17143048)
3. La Vecchia C, Lucchini F, Franceschi S et al (2000) Trends in mortality from primary liver cancer in Europe. Eur J Cancer 36:909-915. (Pubitemid 30214142)
4. Ohtomo K, Furui S, Kokubo T et al (1985) Transcatheter arterial embolization (TAE) in treatment for hepatoma-analysis of threeyear survivors. Radiat Med 3:176-180. (Pubitemid 16130535)
5. Shiina S, Tagawa K, Unuma T et al (1990) Percutaneous ethanol injection therapy for treatment of hepatocellular carcinoma. Am J Roentgenol 154:947-951. (Pubitemid 20133945)
6. Shiina S, Teratani T, Obi S et al (2002) Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 62(Suppl 1):64-68 (Review). (Pubitemid 34702022)
7. Stehlin JS Jr, de Ipolyi PD, Greeff PJ et al (1988) Treatment of cancer of the liver: twenty years' experience with infusion and resection in 414 patients. Ann Surg 208:23-35.
8. Ono Y, Yoshimasu T, Ashikaga R et al (2000) Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 23:564-568. (Pubitemid 32429101)
9. Yoshikawa M, Ono N, Yodono H et al (2008) Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 38:474-483. (Pubitemid 351593948)
10. Sakon M, Nagano H, Dono K et al (2002) Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94:435-442. (Pubitemid 34081374)
11. Obi S, Yoshida H, Toune R et al (2006) Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 106:1990-1997. (Pubitemid 43673215)
12. Glue P, Fang JW, Rouzier-Panis R et al (2000) Pegylated interferon- a2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 68:556-567.
13. Kasai K, Kuroda H, Ushio A et al (2009) Evaluation of newly developed combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon a-2b for advanced hepatocellular carcinoma with portal venous invasion. Hepatol Res 39:117-125.
14. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655. (Pubitemid 13149996)
15. Liver Cancer Study Group of Japan (2000) The general rules for the clinical and pathological study of primary liver cancer, 4th edn. Kanehara, Tokyo, p 19 (in Japanese).
16. Irie T (2001) Intraarterial chemotherapy of liver metastasis: implantation of microcatheter-port system with use of modified fixed catheter tip technique. J Vasc Interv Radiol 12:1215-1218. (Pubitemid 32983360)
17. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216. (Pubitemid 30099779)
18. NCI Common Toxicity Criteria. Common terminology criteria for adverse events v3.0 (CTCAE). Cited 9 August 2006. Available from: http://ctep.cancer. gov/reporting/ctc.html.
19. Fujii T, Takayasu K, Muramatsu Y et al (1993) Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol 23:105-109.
20. Chen SC, Hsieh MY, Chuang WL et al (1994) Development of portal vein invasion and its outcome in hepatocellular carcinoma treated by transcatheter arterial chemo-embolization. J Gastroenterol Hepatol 9:1-6.
21. Schwartz EL, Hoffman M, O'Connor CJ et al (1992) Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells. Biochem Biophys Res Commun 182:1232-1239.
22. Wadler S, Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50:3473- 3486. (Pubitemid 20194083)
23. Elias L, Sandoval JM (1989) Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 163:867-874. (Pubitemid 19236930)
24. Kondo M, Nagano H, Wada H et al (2005) Combination of IFN-a and 5-fluorouracil induces apoptosis through IFN-a/b receptor in human hepatocellular carcinoma cells. Clin Cancer Res 11:1277- 1286. (Pubitemid 40175781)
25. Yano H, Iemura A, Haramaki M et al (1999) Interferon alfa receptor expression and growth inhibition by interferon alpha in human liver cell lines. Hepatology 29:1708-1717. (Pubitemid 29247043)
26. Silva M, Poo J, Wagner F et al (2006) A randomized trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 45: 204-213.
27. Drewinko B, Yang L-Y (1985) Cellular basis for the inefficacy of 5-FU in human colon carcinoma. Cancer Treat Res 69:1391-1398. (Pubitemid 16163078)
28. Guchelaar HJ, Vermes I, Koopmans RP et al (1998) Apoptosis-and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. Cancer Chemother Pharmacol 42:77-83. (Pubitemid 28224995)
29. Ueshima K, Tatsumi C, Sakaguchi Y et al (2006) Breakthrough of the hepatic arterial infusion chemotherapy of hepatocellular carcinoma. Gastroenterology (Tokyo) 43:253-259 (in Japanese).
30. Okada S, Okazaki N, Nose H et al (1992) Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology 16:112-117.
31. Uka K, Aikata H, Takaki S et al (2007) Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 42:845-853. (Pubitemid 47617463)
32. Kantoh T, Abo H, Tomotsu K et al (1993) Prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization (TAE)-significance of repetitive therapies and responses to them within 6 months after the first intervention. Nippon Shokakibyo Gakkai Zasshi 90:1416-1424 (in Japanese). (Pubitemid 23184027)
33. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390.